Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Sales and Divestitures: 2024

Historic Gains from Sales and Divestitures for Janux Therapeutics (JANX) over the last 1 years, with Dec 2024 value amounting to $2,500.

  • Janux Therapeutics' Gains from Sales and Divestitures rose 311.00% to $10,275 in Q3 2025 from the same period last year, while for Sep 2025 it was $10,275, marking a year-over-year increase of 311.00%. This contributed to the annual value of $2,500 for FY2024, which is N/A change from last year.
  • Janux Therapeutics' Gains from Sales and Divestitures amounted to $2,500 in FY2024.
  • Janux Therapeutics' 5-year Gains from Sales and Divestitures high stood at $2,500 for FY2024, and its period low was $2,500 during FY2024.
  • For the 1-year period, Janux Therapeutics' Gains from Sales and Divestitures averaged around $2,500, with its median value being $2,500 (2024).